390 related articles for article (PubMed ID: 24056683)
1. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
[TBL] [Abstract][Full Text] [Related]
2. Personalized therapy for acute myeloid leukemia.
Hourigan CS; Karp JE
Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
4. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
5. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
[TBL] [Abstract][Full Text] [Related]
6. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Man CH; Lam SS; Sun MK; Chow HC; Gill H; Kwong YL; Leung AY
Blood; 2014 Apr; 123(16):2530-9. PubMed ID: 24608976
[TBL] [Abstract][Full Text] [Related]
7. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
8. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
[TBL] [Abstract][Full Text] [Related]
9. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
10. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
Ojamies PN; Kontro M; Edgren H; Ellonen P; Lagström S; Almusa H; Miettinen T; Eldfors S; Tamborero D; Wennerberg K; Heckman C; Porkka K; Wolf M; Kallioniemi O
Leukemia; 2017 May; 31(5):1048-1058. PubMed ID: 27795554
[TBL] [Abstract][Full Text] [Related]
11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
12. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
14. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
Xu B; Zhao Y; Wang X; Gong P; Ge W
Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
[TBL] [Abstract][Full Text] [Related]
15. Precision therapy for acute myeloid leukemia.
Yang X; Wang J
J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
17. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
18. Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing.
Kulesskiy E; Saarela J; Turunen L; Wennerberg K
J Lab Autom; 2016 Feb; 21(1):27-36. PubMed ID: 26721820
[TBL] [Abstract][Full Text] [Related]
19. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
20. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D; Murumägi A; Yadav B; Kontro M; Eldfors S; Kumar A; Karjalainen R; Majumder MM; Ojamies P; Pemovska T; Wennerberg K; Heckman C; Porkka K; Wolf M; Aittokallio T; Kallioniemi O
Leukemia; 2017 May; 31(5):1187-1195. PubMed ID: 27833094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]